Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary
The Stocks Already in Correction Mode (Fox Business)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA


Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters